Mark R. Hake

Mark R. Hake

Mark R. Hake, CFA is a financial analyst and entrepreneur. He has been a Chartered Financial Analyst (CFA) for 31 years and has owned his own investment management and investment research firms that focused on value stocks, both in the U.S. and overseas.

Mark writes over 600 articles per year on stocks, cryptos, SPACs, convertibles, ETFs, and other financial securities. He has been ranked with 5 stars by TipRanks.com (under “Mark R. Hake”) with an average return of over 22% annually and #36 out of 8,116 writers. Presently he authors articles on Medium.com and other sites.

Mark also invests in public and private equities and has acted as a hedge fund manager and portfolio manager for various money management firms. He has also acted as CFO and Chief Strategy Officer for several fin-tech and software companies.

You can follow Mark on LinkedIn and on TipRanks.

Recent Articles

Foresight Autonomous Has Become Another Overvalued EV Stock

Foresight Autonomous has become another overvalued EV stock. FRSX stock is valued too high as the company has no real revenue and profit prospects.

United Airlines Now Says It Will Recover in 2022

United Airlines is still having trouble but will recover in 2022. UAL stock won’t get out of the woods until cash burn is lower.

Stay Away From Money-Losing SunPower Stock After Its Recent Spike

Stay away from money-losing SunPower after its recent spike. SPWR stock is up on speculation even though the company is shutting down one of its solar panel plants.

FuboTV Is Likely To Do Extremely Well Over the Next Year

FuboTV should do well over the next year. FUBO stock is worth at least $51 using a sub comp with NFLX, not including its sports betting deal.

Why Paysafe Looks Even More Undervalued

Paysafe looks even more undervalued. BFT stock is worth about $64.8% more at $25.42 based on its superior profitability in gaming.

Disney Stock Has Some Upside With a Bigger Dividend

Disney will reach new highs after its upcoming earnings release. DIS stock is worth $194 per share if the company increases the dividend.

BioNano Genomics Takes Advantage of a Spike

Bionano Genomics takes advantage of a spike to sell shares at highs. Cash likely represents about 19% of the BNGO stock market capitalization as a result of two capital raises.

Buy More Ethereum for the Same Money, and Watch It Overtake Bitcoin

Ethereum is likely to outperform bitcoin given its history and is cheaper. Ethereum will catch up to Bitcoin sometime within the next 8 to 11 years if past performance continues.

Jaguar Health Stock Remains a Speculative Investment At Best

Jaguar Health stock is a speculative investment at best. JAGX stock is hard to nail down as it’s hard to understand its numerous and strange financings.

Affirm Stock Is Overvalued Given Its Massive Loan Losses

Don't believe in Affirm stock as its loan losses are too hard to accept. AFRM stock is overvalued given its massive loan losses last year.